TriSalus Life Sciences (NASDAQ:TLSI) Issues Quarterly Earnings Results, Meets Estimates

TriSalus Life Sciences (NASDAQ:TLSI) issued its quarterly earnings results on Thursday. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16), FiscalAI reports. The business had revenue of $11.41 million for the quarter, compared to the consensus estimate of $10.27 million.

Here are the key takeaways from TriSalus Life Sciences’ conference call:

• Q2 revenue reached $11.4 million, up sequentially and 1.7% year over year, while gross margin improved to 86.8% from 83.9% due to lower unit costs and manufacturing improvements.
• CMS issued a new G-code extending TriNav reimbursement into physician office-based labs, broadening access beyond hospitals and ambulatory surgery centers and potentially supporting adoption in liver, uterine, prostate, and genicular embolization.
• TriSalus has 11 active clinical studies across 27 sites involving more than 400 treated patients; additional trials are launching in the second half of 2026, while PETER data has been submitted for peer-reviewed publication and TriNav Advance remains under FDA review.
• Management reiterated 2026 revenue guidance of $54 million to $57 million, representing 19%–26% growth, and expects sequential growth acceleration in the second half as the expanded sales force becomes more productive and first-half expansion costs decline.
• The commercial build-out increased sales and marketing expenses to $11.4 million from $7.2 million, contributing to a wider adjusted EBITDA loss of $7.1 million versus $5.3 million a year earlier, although management said its $46.3 million cash balance funds the strategic plan.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock traded up $0.74 on Friday, reaching $5.61. The stock had a trading volume of 700,814 shares, compared to its average volume of 307,538. TriSalus Life Sciences has a 12 month low of $2.20 and a 12 month high of $7.95. The firm has a market capitalization of $344.55 million, a price-to-earnings ratio of -3.98 and a beta of 0.43. The firm’s 50-day moving average is $4.12 and its two-hundred day moving average is $4.30. The company has a quick ratio of 5.46, a current ratio of 5.78 and a debt-to-equity ratio of 2.58.

Wall Street Analysts Forecast Growth

TLSI has been the topic of several analyst reports. Lake Street Capital dropped their target price on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings downgraded TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.50.

Insider Buying and Selling

In other TriSalus Life Sciences news, Director Mats Wahlstrom acquired 60,000 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $2.53 per share, with a total value of $151,800.00. Following the completion of the transaction, the director directly owned 147,555 shares in the company, valued at approximately $373,314.15. This represents a 68.53% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Michael P. Stansky bought 410,000 shares of TriSalus Life Sciences stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $2.50 per share, with a total value of $1,025,000.00. Following the completion of the purchase, the director directly owned 1,240,722 shares in the company, valued at $3,101,805. This trade represents a 49.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 719,682 shares of company stock worth $1,804,176. Company insiders own 16.30% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of TriSalus Life Sciences in the second quarter valued at about $47,000. Invesco Ltd. acquired a new stake in shares of TriSalus Life Sciences during the 4th quarter worth about $72,000. Abel Hall LLC acquired a new stake in shares of TriSalus Life Sciences during the 4th quarter worth about $73,000. Finally, Man Group plc bought a new stake in shares of TriSalus Life Sciences during the 4th quarter worth about $102,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.